Please use this identifier to cite or link to this item:
Title: A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer.
Austin Authors: Roberts, Matthew J;Papa, Nathan;Perera, Marlon ;Scott, Susan;Teloken, Patrick E;Joshi, Andre;Vela, Ian;Pryor, David;Martin, Jarad;Woo, Henry
Affiliation: Department of Urology, Austin Health, Heidelberg, Victoria, Australia
Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW, Australia
Princess Alexandra Hospital, Brisbane, Qld, Australia
Faculty of Medicine, University of Queensland, Brisbane, Qld, Australia
Nepean Urology Research Group, Kingswood, NSW, Australia
Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
Australian Prostate Cancer Research Centre, Queensland University of Technology, Brisbane, Qld, Australia
Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia
Calvary Mater Newcastle, Waratah, NSW, Australia
Issue Date: Nov-2019 2019-09-05
Publication information: BJU International 2019; 124 (Suppl 1): 31-36
Abstract: To characterize national clinical practice trends in the treatment of prostate cancer (PCa) in Australia. Population-level data were extracted from existing Medicare Benefits Schedule data for radical prostatectomy (RP) and brachytherapy (2002-2016), as well as external beam radiotherapy (EBRT; 2012-2016). Treatment rates were calculated relative to whole and PCa populations among privately treated patients. Overall age-related and geographical trends were analysed. The use of RP and low-dose-rate (LDR) brachytherapy increased between 2002 and 2009, but subsequently decreased to 124 and 6.9 per 100 000 men, respectively, in 2016. More dramatic decreases were observed for men aged <65 years. From 2012, rates of RP (15% drop) and LDR brachytherapy (58% drop) decreased, while the use of EBRT remained steady, falling by 5% to 42 per 100 000 men in 2016. Overall treatment increased in the age group 75-84 years, with the rate of RP increasing by 108%. National claims data indicate there has been a reduction in PCa treatment since 2009, which is mostly attributable to a reduction in the treatment of younger patients and reduced use of brachytherapy. RP is most commonly used and its use is rising in men aged >65 years.
DOI: 10.1111/bju.14773
ORCID: 0000-0003-0552-7402
PubMed URL: 31486575
Type: Journal Article
Subjects: #PCSM
practice patterns
prostatic neoplasms
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.